NEOGENOMICS INC — Director's Dealing 2021

Dec 31, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NEOGENOMICS INC (NEO)
CIK: 0001077183
Period of Report: 2021-12-30

Reporting Person: McKenzie Kathryn B (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-12-30	Common Stock	A	30572	—	Acquired	47261	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$9.07	2022-10-18	Common Stock (20000.0)	20000	Direct
Stock Option (Right to Buy)	$8.03	2023-02-26	Common Stock (40000.0)	40000	Direct
Stock Option (Right to Buy)	$19.6	2024-03-01	Common Stock (13894.0)	13894	Direct
Stock Option (Right to Buy)	$28.33	2027-03-02	Common Stock (37514.0)	37514	Direct
Stock Option (Right to Buy)	$53.17	2028-03-02	Common Stock (35171.0)	35171	Direct

Footnotes

F1: On December 30, 2021, Ms. McKenzie was granted 30,572 restricted stock awards. These awards vest ratably over three years with the first tranche vesting on December 31, 2022.

F2: On October 17, 2017, Ms. McKenzie was granted 25,000 stock options. These options vested ratably over the first three anniversary dates of the grant date.

F3: On February 26, 2018, Ms. McKenzie was granted 48,000 stock options. These options vested ratably over the first three anniversary dates of the grant date.

F4: On March 1, 2019, Ms. McKenzie was granted 13,894 stock options. These options vest ratably over the first four anniversary dates of the grant date.

F5: On March 2, 2020, Ms. McKenzie was granted 37,514 stock options. These options vest ratably over the first four anniversary dates of the grant date.

F6: On March 2, 2021, Ms. McKenzie was granted 35,171 stock options. These options vest ratably over the first four anniversary dates of the grant date.